TE1 Stoklara Genel Bakış Bio-Techne Corporation, iştirakleriyle birlikte, dünya çapında araştırma, teşhis ve biyoişleme pazarları için yaşam bilimleri reaktifleri, cihazları ve hizmetleri geliştirmekte, üretmekte ve satmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Bio-Techne Corporation Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Bio-Techne Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$69.00 52 Haftanın En Yüksek Seviyesi US$78.50 52 Haftanın En Düşük Seviyesi US$57.50 Beta 1.27 1 Aylık Değişim -2.82% 3 Aylık Değişim 3.76% 1 Yıllık Değişim 4.55% 3 Yıllık Değişim -26.98% 5 Yıllık Değişim 43.01% Halka arzdan bu yana değişim 502.88%
Son Haberler & Güncellemeler
Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo Nov 14
New minor risk - Earnings quality Nov 08
Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer (SITC) 39Th Annual Meeting Nov 06
Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data Nov 05
First quarter dividend of US$0.08 announced Nov 04
First quarter 2025 earnings released: EPS: US$0.21 (vs US$0.32 in 1Q 2024) Nov 01 Daha fazla güncelleme görün
Bio-Techne Corporation to Highlight Novel Solutions for Cancer and Carrier Screening At Amp 2024 Annual Meeting & Expo Nov 14
New minor risk - Earnings quality Nov 08
Bio-Techne Corporation to Present at the Society for Immunotherapy of Cancer (SITC) 39Th Annual Meeting Nov 06
Bio-Techne Corporation Announces the Release of Clinically Relevant Spatial Biology Data Nov 05
First quarter dividend of US$0.08 announced Nov 04
First quarter 2025 earnings released: EPS: US$0.21 (vs US$0.32 in 1Q 2024) Nov 01
Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2024, Payable on November 22, 2024 Oct 30
ScaleReady and Bio-Techne Corporation Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies Sep 16
Bio-Techne Corporation, Annual General Meeting, Oct 24, 2024 Sep 13
Fourth quarter dividend of US$0.08 announced Aug 12
Full year 2024 earnings released: EPS: US$1.07 (vs US$1.81 in FY 2023) Aug 08
Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2024, Payable on August 30, 2024 Aug 07
Bio-Techne Corporation Announces the Launch of the Leo™ System Jul 31
Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex™? System at the Annual ASMS Conference May 30
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration May 23
Investor sentiment improves as stock rises 21% May 08
Third quarter dividend of US$0.08 announced May 05
Third quarter 2024 earnings released: EPS: US$0.31 (vs US$0.45 in 3Q 2023) May 02
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024 May 01
Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors Apr 30
Now 20% overvalued Apr 30
Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay Apr 27
Independent Director recently sold €733k worth of stock Mar 12
Second quarter dividend of US$0.08 announced Feb 05
Second quarter 2024 earnings released: EPS: US$0.17 (vs US$0.32 in 2Q 2023) Feb 02
Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended December 31, 2023, Payable February 26, 2024 Feb 02
Bio-Techne Corporation Sets New Standard with the Development of A Next-Generation, Protease-Free RNAscope Spatial Multiomics Workflow Jan 29
Now 22% overvalued after recent price rise Jan 24
Bio-Techne Corporation to Report Q2, 2024 Results on Feb 01, 2024 Jan 17 Bio-Techne Corporation Appoints Matthew F. Mcmanus as President, Diagnostics and Genomics Segment, Effective January 8, 2024
Bio-Techne Corporation Announces to Pay A Dividend for the Quarter Ended September 30, 2023, Will Be Payable November 24, 2023 Nov 01
First quarter 2024 earnings released: EPS: US$0.32 (vs US$0.57 in 1Q 2023) Nov 01
Bio-Techne Corporation to Present New Data Using Lunaphore's Comet Technology at the Society for Immunotherapy of Cancer's 38th Annual Meeting Oct 27 Bio-Techne Corporation Announces Executive Changes
Bio-Techne Corporation Launches the New Maurice Chromeleon Driver Kit, Which Enables Control of its Maurice™ Instrument with the Thermo Scientific™ Chromeleon™ Chromatography Data System Sep 27
Bio-Techne Corporation, Annual General Meeting, Oct 26, 2023 Sep 14
Full year 2023 earnings released: EPS: US$1.82 (vs US$1.73 in FY 2022) Aug 09
Bio-Techne Corporation (NasdaqGS:TECH) acquired Lunaphore Technologies SA from PHC Holdings Corporation (TSE:6523) and others. Jul 11
Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Lunaphore Technologies SA. Jun 23
Bio-Techne Corporation Announces Launch of Kappa and Lambda Rnascope Ish Probes as Analyte Specific Reagents (Asrs) for the Detection of Immunoglobulin Kappa and Lambda Light Chains mRNA May 11
Bio-Techne Declares Quarterly Dividend, Payable May 26, 2023 May 04
Third quarter 2023 earnings released: EPS: US$0.45 (vs US$0.39 in 3Q 2022) May 03
Second quarter 2023 earnings released: EPS: US$0.32 (vs US$0.51 in 2Q 2022) Feb 05
Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2022, Payable on February 27, 2023 Feb 03
Bio-Techne Corporation Announces Executive Changes, Effective March 3, 2023 Feb 01
Bio-Techne Launches the Mauriceflex™ System, Adding Cief Fractionation Capability to the Gold Standard Maurice Assays Jan 27
Bio-Techne Corporation Launches RNAscope Plus Assay to Advance Gene Therapy Development Jan 11
Bio-Techne Releases MitoBrilliant Fluorescent Dyes, Providing A Next-Generation Tool for Imaging Mitochondria in Live and Fixed Cells Dec 06
Insufficient new directors Nov 16
First quarter 2023 earnings released: EPS: US$2.28 (vs US$1.78 in 1Q 2022) Nov 02
Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2022, Payable on November 28, 2022 Nov 02
Bio-Techne Corporation Announces the Introduction of 3 Novel TSA Vivid Fluorophores for Highly Sensitive Fluorescent Detection of RNAs and Proteins in Cells and Tissues Oct 13
Bio-Techne Corporation and PROGEN Introduce New Simple Plex AAV Viral Titer Assays Oct 12
Bio-Techne Corporation Commercializes Automated Multi-Omic Rnascope Assays for Spatial Visualization of RNA and Protein Biomarkers in FFPE Tissues Oct 07
Bio-Techne Corporation, Annual General Meeting, Oct 27, 2022 Sep 02
Bio-Techne Corporation Announces Release of Quantist Luminex Data Analysis Software Aug 19
Full year 2022 earnings released: EPS: US$6.94 (vs US$3.62 in FY 2021) Aug 05 Bio-Techne Corporation Announces Dividend for the Quarter Ended June 30, 2022, Payable on August 29, 2022
Insufficient new directors Aug 01
Bio-Techne Launches New Turbo CE-SDS ™ Cartridge, Accelerating Protein Purity Analysis Throughput by 400% Jul 13
Bio-Techne Announces Launch of the CE-IVD RNAscope ISH Probe High Risk HPV Assay for Head and Neck Cancer Jul 07
Bio-Techne Corporation (NasdaqGS:TECH) completed the acquisition of Namocell, Inc. Jul 06
Insufficient new directors Jul 02 Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Growth-Defensive Index
Bio-Techne Corporation (NasdaqGS:TECH) reached an agreement to acquire Namocell, Inc. Jun 23
Bio-Techne Corporation Announces the Publication of A Global Study in the Journal of Electrophoresis May 26
Independent Chairman of the Board recently bought €100k worth of stock May 12
Third quarter 2022 earnings released: EPS: US$1.55 (vs US$1.18 in 3Q 2021) May 05
Bio-Techne Corporation Declares Quarterly Dividend for the Quarter Ended March 31, 2022, Payable on May 27, 2022 May 05
Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduces New Simple Plex Hek 293 Hcp 3G Immunoassay Apr 13
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 04 Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2021, Payable on February 25, 2022
Now 20% undervalued after recent price drop Jan 28
Bio-Techne Corporation Announces Commercial Release of High Sensitivity Fluorescent Detection Stellar NIR / IR™ Modules for Jess Automated Western Blotting System Jan 19
First quarter 2022 earnings released: EPS US$1.78 (vs US$0.87 in 1Q 2021) Nov 03
Bio-Techne Launches ExCellerate iPSC Expansion Medium Sep 15
President of Protein Sciences Segment recently sold €656k worth of stock Sep 03
Full year 2021 earnings released: EPS US$3.62 (vs US$6.00 in FY 2020) Aug 06 Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 3000E Value Index
Bio-Techne Corporation(NasdaqGS:TECH) dropped from Russell 1000 Value-Defensive Index Jun 27
President of Diagnostics & Genomics recently sold €288k worth of stock Jun 12
President of Diagnostics & Genomics recently sold €293k worth of stock May 28
Bio-Techne Corporation Announces Results of A Multisite Evaluation Study of the AmplideX May 11
Third quarter 2021 earnings released: EPS US$1.18 (vs US$0.95 in 3Q 2020) May 08
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2021, Payable on May 28, 2021 May 07
Bio-Techne Announces Commercial Release of Novel DNAscope™ in situ Hybridization Assays for Chromogenic Detection of DNA Copy Number and Structural Variations Apr 29
Bio-Techne Corporation (NasdaqGS:TECH) has reached an agreement to acquire Asuragen, Inc for $320 million. Mar 05
Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana Mar 03
Bio-Techne and Luminary Therapeutics Sign License Agreement for Use of Bio-Techne's Tcbuster™ for the Development of Luminary's Car-T Cell Therapies Feb 24
New 90-day high: €342 Feb 18
Bio-Techne Corporation Announces That the U.S. Food and Drug Administration Added Covid-Seroklir to the Emergency Use Authorization Feb 11 Hissedar Getirileri TE1 DE Life Sciences DE Pazar 7D -0.7% 0.2% 0.7% 1Y 4.5% -2.4% 8.4%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: TE1 geçen yıl % -2.4 oranında getiri sağlayan German Life Sciences sektörünü aştı.
Getiri vs Piyasa: TE1 geçen yıl % 8.4 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is TE1's price volatile compared to industry and market? TE1 volatility TE1 Average Weekly Movement 5.3% Life Sciences Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: TE1 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: TE1 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bio-Techne Corporation, iştirakleriyle birlikte, dünya çapında araştırma, teşhis ve biyoişleme pazarları için yaşam bilimleri reaktifleri, cihazları ve hizmetleri geliştirmekte, üretmekte ve satmaktadır. Şirket, Protein Bilimleri ve Teşhis ve Genomik olmak üzere iki segmentte faaliyet göstermektedir. Protein Bilimleri segmenti, sitokinler ve büyüme faktörleri, antikorlar, küçük moleküller, doku kültürü serumları ve hücre seçim teknolojileri gibi yaşam bilimleri araştırmaları, teşhis ve hücre ve gen terapisinin çeşitli yönlerinde kullanılan biyolojik reaktifler geliştirmekte ve üretmektedir.
Daha fazla göster Bio-Techne Corporation Temel Bilgiler Özeti Bio-Techne'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? TE1 temel i̇stati̇sti̇kler Piyasa değeri €11.15b Kazançlar(TTM ) €146.82m Gelir(TTM ) €1.14b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) TE1 gelir tablosu (TTM ) Gelir US$1.17b Gelir Maliyeti US$398.40m Brüt Kâr US$773.19m Diğer Giderler US$622.50m Kazançlar US$150.68m
Temettüler
0.4% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/02 10:39 Gün Sonu Hisse Fiyatı 2025/01/02 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2024/06/30
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Bio-Techne Corporation 27 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum David Toung Argus Research Company James Francis Mainwaring Atlantic Equities LLP Catherine Ramsey Schulte Baird
Göster 24 daha fazla analist 
